Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

PROTEIN-rige måltider til at kontrollere glukose (PROTIME)

26. september 2026 opdateret af: Olga Ramich (formerly Pivovarova), German Institute of Human Nutrition

Måltidsbaserede strategier til forbedring af glukosemetabolismen ved prædiabetes og type 2-diabetes

The overall aim is to identify the dietary pattern for prevention and treatment of type 2 diabetes. The specific aim of this pilot project is to compare effects of two diets with different diurnal distribution of carbohydrates and protein on the glucose metabolism in subjects with prediabetes and type 2 diabetes and its effects on inflammatory status.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Overweight individual with prediabetes and non-insulin treated type 2 diabetes will be recruited for the study. The trial will have a cross-over design and compare metabolic effects of two isocaloric 4-week interventions with opposite timely distribution of macronutrient intake - a high-protein (HP) breakfast and a high-carb (HC) dinner (HP/HC intervention) vs. a HC breakfast and a HP dinner (HC/HP intervention) - divided by a 4-week wash-out phase. A HP low-carb meal (breakfast or dinner) will contain 35%E protein, 35%E carbs, and 30%E fat, and a HC meal (breakfast or dinner) will contain 10E%protein, 60%E carbs, and 30%E fat.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

30

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Potsdam-Rehbrücke
      • Potsdam, Potsdam-Rehbrücke, Tyskland, 14558
        • Olga Ramich

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Prediabetes (fasting blood sugar 100-125 mg/dl)
  • Diabetes type 2 (fasting blood sugar >126 mg/dl)
  • Overweight and obesity (BMI 25-50 kg/m2)

Exclusion Criteria:

  • Other diabetes types
  • Insulin treatment
  • Shift work
  • Weight changes >5% within past 3 months
  • Systemic glucocorticoid therapy
  • Systemic infections
  • Severe anemia
  • High blood pressure (>180/110 mmHg)
  • Endocrinologic, liver and heart disorders
  • Immune diseases
  • Thyroid dysfunction
  • Heart attack or stroke
  • Cancer in the last 2 years
  • Eating disorders, food intolerance/allergy, addiction disorders, digestive disorders intestinal, liver, cardiovascular diseases
  • Hereditary or acquired coagulation disorders
  • Non-interruptible intake of blood thinners (anticoagulants)
  • Specific diets, intermittent fasting
  • Pregnancy or breastfeeding
  • Severe internal or psychiatric disorders or other conditions and drugs therapy that might influence the outcome of the study

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: HP/HC - HC/HP

Isocaloric 4-week HP/HC intervention followed by a 4-week HC/HP intervention.

The intervention is about an isocaloric diet that differs in terms of distribution of carbohydrates and protein throughout the day. The interventions include a HP-breakfast and a HC-dinner vs. a HC-breakfast and a HP-dinner. A HP low-carb meal (breakfast or dinner) will contain 35%E protein, 35%E carbs, and 30%E fat, and a HC meal (breakfast or dinner) will contain 10%E protein, 60%E carbs, and 30%E fat.

Eksperimentel: HC/HP - HP/HC

Isocaloric 4-week HC/HP intervention followed by a 4-week HP/HC intervention.

The intervention is about an isocaloric diet that differs in terms of distribution of carbohydrates and protein throughout the day. The interventions include a HP-breakfast and a HC-dinner vs. a HC-breakfast and a HP-dinner. A HP low-carb meal (breakfast or dinner) will contain 35%E protein, 35%E carbs, and 30%E fat, and a HC meal (breakfast or dinner) will contain 10%E protein, 60%E carbs, and 30%E fat.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Mean 24-hour glucose
Tidsramme: 4 weeks

Mean 24-hour glucose assessed by continuous glucose monitoring (CGM)

4 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Measurement of height
Tidsramme: 4 weeks

Height measured by stadiometer

4 weeks
Measurement of body weight
Tidsramme: 4 weeks

Body weight measured by body scale

4 weeks
Waist and hip circumference / waist to hip ratio
Tidsramme: 4 weeks

Waist and hip circumference measured by tape measure

4 weeks
Systolic and diastolic blood pressure
Tidsramme: 4 weeks

Systolic and diastolic blood pressure changes measurement by manometer

4 weeks
Body fat and lean mass
Tidsramme: 4 weeks

Body fat and lean mass assessed by bioelectrical impendance analysis (BIA)

4 weeks
Energy expenditure and substrate oxidation rates
Tidsramme: 4 weeks

Energy expenditure and substrate oxidation rates assessed by indirect calorimetry

4 weeks
Hepatic values (gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT))
Tidsramme: 4 weeks

GGT, AST, ALT etermined in fasting blood samples

4 weeks
Renal values (creatinine, urea, uric acid)
Tidsramme: 4 weeks

Renal values determined in fasting blood samples

4 weeks
Intra- und inter-day glycemic variability
Tidsramme: 4 weeks

Indices of intra- and inter-day glycemic variability assessed by continuous glucose monitoring (CGM)

4 weeks
Glucose levels in meal tolerance test (MTT)
Tidsramme: 4 weeks

Glucose levels in blood samples collected in MTT

4 weeks
Metabolic hormones (insulin, C-peptide, glucagon, glucagon-like peptite 1(GLP-1), gastric inhibitory polypeptide (GIP), peptide YY (PYY), ghrelin, adiponectin, leptin)
Tidsramme: 4 weeks

Blood levels of metabolic hormones assessed in fasting state and during the MTT

4 weeks
Inflammatory markers and T cell populations analyses
Tidsramme: 4 weeks

Level of the inflammatory markers IL-6, TNFa, MCP-1 and T cell populations in circulation and adipose tissue are assessed through blood analysis and fat biopsy

4 weeks
Satiety and hunger scores
Tidsramme: 4 weeks

Satiety and hunger scores assessed using Visual Analog Scale (VAS with a scale of 1-100, where higher values correspond to stronger satiety/hunger)

4 weeks
Sleep/wake timing and sleep quality
Tidsramme: 4 weeks

Sleep/wake timing and sleep quality assessed by the Pittsburgh Sleep Quality Index (PSQI score, which ranges from 0-21, where higher values correspond to worse sleep quality) and also monitored by an ActiGraph device

4 weeks
Physical activity
Tidsramme: 4 weeks

24-h physical activity will be monitored by an ActiGraph device

4 weeks
Adipose tissue transcriptome
Tidsramme: 4 weeks

RNA-Seq analysis of subcutaneous adipose tissue sample

4 weeks
Gene expression in peripheral blood mononuclear cells (PBMC)
Tidsramme: 4 weeks

Expression of metabolic genes assessed by qPCR

4 weeks
Gut microbiota and microbiome-derived metabolites
Tidsramme: 4 weeks

Determined in stool samples and blood plasma

4 weeks
Determination of decision behavior
Tidsramme: 4 weeks

Impulsiveness assessed by decision making tasks on computer

4 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Olga Ramich, PD Dr., German Institute of Human Nutrition

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

12. april 2024

Primær færdiggørelse (Faktiske)

21. april 2026

Studieafslutning (Anslået)

28. februar 2027

Datoer for studieregistrering

Først indsendt

15. marts 2024

Først indsendt, der opfyldte QC-kriterier

21. april 2024

Først opslået (Faktiske)

24. april 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

26. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 90/2023

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .